Welcome to our dedicated page for Tango Therapeutics news (Ticker: TNGX), a resource for investors and traders seeking the latest updates and insights on Tango Therapeutics stock.
Tango Therapeutics, Inc. (TNGX) is a clinical-stage biotechnology company pioneering precision oncology solutions through innovative target discovery and therapeutic development. This page provides authorized updates on their research programs, clinical trials, and strategic initiatives in cancer treatment innovation.
Investors and researchers will find verified information about TNGX's pipeline progress, including PRMT5 inhibitor developments for CNS/non-CNS cancers and discontinued programs like TNG348. All content undergoes strict verification to ensure accuracy in reporting scientific milestones and regulatory updates.
Key coverage areas include clinical trial phases, research collaborations, peer-reviewed study publications, and corporate developments. The resource is particularly valuable for tracking therapies addressing tumor suppressor gene restoration and immune evasion mechanisms.
Bookmark this page for real-time updates on Tango Therapeutics' work in CRISPR-enabled drug discovery and their mission to transform cancer treatment paradigms through precision medicine approaches.
Tango Therapeutics (NASDAQ: TNGX) has discontinued its TNG348 program following Phase 1/2 trial results indicating liver toxicity in patients. The company emphasizes patient safety as the primary reason for halting the development of TNG348, a USP1 inhibitor. This decision will allow Tango Therapeutics to redirect resources toward its PRMT5 and CoREST clinical programs, which remain on track. The company has extended its cash runway into 2027 and plans to provide a comprehensive clinical update on TNG908 and TNG462 in the latter half of the year.
Tango Therapeutics, Inc. (NASDAQ: TNGX) reported strong financial results for Q1 2024 with a cash position of $344 million. The company is progressing its clinical programs, including dose expansion in TNG908 and TNG462 trials, with clinical data expected in 2H 2024. Tango is well-funded through late 2026. The company welcomed Julie Carretero as Chief Human Resources Officer to support growth.
FAQ
What is the current stock price of Tango Therapeutics (TNGX)?
What is the market cap of Tango Therapeutics (TNGX)?
